| |
No treatment group |
Statins-treatment group |
p-value |
| Number |
121 |
59 |
|
| Men (%) |
73.6 |
57.6 |
0.04 |
| Age (years) |
60.9 ± 11.4 |
67.0 ± 9.9 |
<0.0001 |
| Duration of diabetes (years) |
12.7 ± 9.2 |
16.6 ± 8.8 |
0.007 |
| Body Mass Index (kg/m2) |
25.0 ± 4.9 |
26.7 ± 4.0 |
0.029 |
| Waist circumference (cm) |
89.1 ± 10.8 |
93.0 ± 9.8 |
0.019 |
| Systolic Blood Pressure (mmHg) |
133.6 ± 12.2 |
135.2 ± 15.8 |
N.S |
| Diastolic Blood Pressure (mmHg) |
74.9 ± 10.0 |
71.9 ± 12.5 |
N.S |
| Total cholesterol (mg/dL) |
221.2 ± 32.9 |
204.8 ± 28.9 |
0.001 |
| Triglycerides (mg/dL) |
136.0 ± 152.9 |
166.3 ± 145.3 |
N.S |
| HDL cholesterol (mg/dL) |
55.7 ± 14.9 |
54.6 ± 13.3 |
N.S |
| LDL cholesterol (mg/dL) |
137.2 ± 26.6 |
115.9 ± 22.9 |
<0.001 |
| RLP cholesterol (mg/dL) |
6.7 ± 16.4 |
7.0 ± 9.2 |
N.S |
| Cholesterol absorption marker/total cholesterol (μg/mg*103) |
27.4 ± 9.3 |
33.5 ± 18.3 |
<0.05 |
| Cholesterol synthesis maker/total cholesterol (μg/mg*103) |
9.1 ± 5.1 |
5.8 ± 3.5 |
<0.001 |
| A1C (%) |
7.4 ± 1.0 |
7.6 ± 1.1 |
N.S |
| Fasting blood glucose (mg/dL) |
138.6 ± 43.1 |
139.1 ± 46.3 |
N.S |
| C-Peptide Reactivity (ng/mL) |
1.7 ± 1.0 |
2.1 ± 1.7 |
N.S |
| Concomitant drugs (%) |
|
|
|
| Sulfonylurea drugs |
40.5 |
47.5 |
N.S |
| α-glucosidase inhibitors |
24.0 |
32.2 |
N.S |
| Biguanides/Thiazolidinediones |
31.4 |
49.2 |
0.023 |
| Insulin |
33.1 |
52.5 |
0.015 |
| Antihypertensive drugs |
38.0 |
76.3 |
<0.001 |
| Antiplatelet agents |
17.6 |
36.2 |
0.008 |
| Risk factors (%) |
|
|
|
| Smoker |
19.0 |
15.3 |
N.S |
| Family history of coronary artery disease |
3.3 |
5.1 |
N.S |
| History of coronary artery disease |
4.2 |
18.6 |
0.004 |
| History of stroke |
7.5 |
5.1 |
N.S |
| History of peripheral artery disease |
0.8 |
1.7 |
N.S |
C-peptide reactivity (reference value): 1.2 to 2.0 ng/mL. Data are expressed as mean ± SD. HDL, high-density lipoprotein; LDL, low-density lipoprotein; RLP, remnant-like
particle; A1C, hemoglobin A